Repaglinide, 1 a non-sulfonyl urea oral hypoglycemic agent of the meglitinide class, is mainly used in the management of type II diabetes mellitus. Chemically, repaglinide is a S(+)2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl) benzoic acid, and is not yet official in any Pharmacopoeia. So far, no assay procedure has been reported for the determination of this drug in its pharmaceutical formulations.
Apparatus
Quantitative HPLC was performed on a gradient high pressure liquid chromatograph (Shimadzu HPLC Class 10Aseries) with two LC-10AT pumps, a fixed wavelength programmable UV/VIS detector (SPD-10A), a guard column (ShimadzuTM, ODS 2 cm, Shim-pack) and RP C-18 column (150 mm × 4.6 mm i.d., particle size 5 µ) was used. The HPLC system was equipped with the software "Class LC-10AT series version 5.03" (Shimadzu).
HPLC conditions
The contents of the mobile phase were methanol and 0.1% v/v triethylamine (pH adjusted to 7 with 1% v/v ortho-phosphoric acid) in the ratio of 50:50 v/v. They were filtered before use through a 0.45 µm membrane filter, degassed with a helium spurge for 15 min and pumped from the respective solvent reservoirs to the column at a flow rate of 1 ml/min, which yielded a column back pressure of 120 -140 kg/cm 2 . The run time was set at 5 min and the column temperature was maintained at 30˚C. The volume of injection loop was 20 µl. Prior to injection of the drug solutions, the column was equilibrated for at least 30 min with the mobile phase flowing through the systems. The eluents were monitored at 235 nm and the data were acquired, stored and analyzed with the software Class LC-10AT series version (Shimadzu).
Recommended procedure
A stock solution of the drug and internal standard was prepared by dissolving 25 mg of repaglinide and nimesulide in a 25 ml volumetric flask containing methanol (HPLC grade) sonicated for about 15 min and then made up to volume with methanol. Daily working standard solutions of repaglinide and nimesulide were prepared by suitable dilution of the stock solution with the mobile phase. Five sets of the drug solution were prepared in the mobile phase containing repaglinide at a concentration of 0.1 -0.5 µg/ml along with a fixed concentration (0.1 µg/ml) of nimesulide as internal standard. Each of these drug solutions (20 µl) was injected six times into the column and the peak area and retention time was recorded.
Procedure for pharmaceutical formulations
Not fewer than twenty tablets were weighed to obtain the average tablet weight and were then powdered. A sample of the powdered tablets, claimed to contain 25 mg of the active ingredient was mixed with 25 mg of nimesulide (Internal Standard) in a 25 ml volumetric flask. The contents were dissolved in the volume that was made up with methanol. This mixture was shaken well and was then filtered through a 0.45 µm membrane filter. An aliquot of this solution (1.0 ml) was volume with mobile phase to get a concentration of 100 µg/ml. From this, 1 µg/ml of the solution was prepared. Various volumes of this aliquot were diluted to get concentrations between 80 -120% of test concentration with mobile phase. All determinations were conducted in triplicate.
The same procedure was used to estimate the concentration of the drug in two different strengths of repaglinide tablets (Table 3) .
Results and Discussion
The development of HPLC methods for the determination of drugs has received considerable attention in recent years because of their importance in the quality control of drugs and drug products. The goal of this study was to develop a rapid HPLC method for the analysis of repaglinide in its pharmaceutical dosage form, using the most commonly employed RP C-18 column with UV detection.
The retention time (tR) of repaglinide and internal standard nimesulide were found to be 3.40 and 2.04 min, respectively. A typical chromatogram formulation of repaglinide and internal standard is shown in Fig. 1 . The calibration curve of repaglinide was constructed by plotting the ratio of the peak area of repaglinide to the peak area of internal standard (Y) against concentration (X). It was found to be linear with a correlation coefficient of 0.9983, the representative linear regression equation being Y = 2.2400 + 23.2200X. This method was validated for its intra and inter-day precision. In the range of 0.1 -0.5 µg/ml, the relative standard deviations, based on the peak area ratios for five triplicate injections were found to be between 0.06% and 1.24% (Table 1 ). The inter-assay precision (3 days, n = 6) was expressed as relative standard deviation and range between 0.15% and 1.15% (Table 2) .
The HPLC developed in the present study was used to quantify repaglinide in tablet dosage forms. Repaglinide tablets (0.5 mg, 1.0 mg and 2.0 mg) were analyzed. The obtained results are given in Table 3 . The average drug content was found to be 102.71% of the labeled amount. No interfering peaks were found in the chromatogram, indicating that the tablet excipients did not interfere with the estimation of the drug by the proposed HPLC method. Also, when a known amount of the drug solution was added to a powdered sample of the tablet dosage form and subjected to an estimation of the drug by the proposed method, there was a high recovery (Table 4) of repaglinide (100.71 ± 0.42%), indicating that the proposed procedure for the determination of repaglinide in the tablet dosage forms is highly accurate.
The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate. It will be useful for the determination of repaglinide in its pharmaceutical dosage forms. ANALYTICAL SCIENCES DECEMBER 2003, VOL. 19 
